Nuvation Bio Inc (NUVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has a cash flow conversion efficiency ratio of 0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.07 Million) by net assets ($319.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nuvation Bio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Nuvation Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nuvation Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvation Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coty Inc
NYSE:COTY
|
-0.060x |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
0.046x |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
0.215x |
|
Atrium Ljungberg AB (publ)
ST:ATRLJ-B
|
0.005x |
|
Grupo Gigante S. A. B. de C. V
MX:GIGANTE
|
0.046x |
|
Faraday Technology Corp
TW:3035
|
-0.038x |
|
SÜSS MicroTec SE
F:SMHN
|
0.019x |
|
Montana Aerospace AG
SW:AERO
|
0.050x |
Annual Cash Flow Conversion Efficiency for Nuvation Bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Nuvation Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.72 Million | $-173.43 Million | -0.567x | -101.74% |
| 2024-12-31 | $463.79 Million | $-130.41 Million | -0.281x | -150.23% |
| 2023-12-31 | $605.12 Million | $-68.00 Million | -0.112x | +23.41% |
| 2022-12-31 | $655.08 Million | $-96.11 Million | -0.147x | -60.50% |
| 2021-12-31 | $746.00 Million | $-68.19 Million | -0.091x | +46.18% |
| 2020-12-31 | $215.08 Million | $-36.53 Million | -0.170x | +18.15% |
| 2019-12-31 | $117.75 Million | $-24.43 Million | -0.207x | -125.06% |
| 2018-12-31 | $-744.00K | $-616.00K | 0.828x | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more